EXACT Therapeutics: Warrants exercise by leading shareholders and primary insiders

05 Feb 2026 09:17 CET

Oslo, Norway, 5 February 2026. Reference is made to the stock exchange
announcement by EXACT Therapeutics AS (the "Company", Euronext Growth ticker:
EXTX), a clinical-stage precision medicine company, earlier today on 5 February
2026, confirming that GE Medical Holdings AB (“GEMH”) will exercise of all of
its 26,973,169 warrants.

The Company is pleased to announce that the following major shareholders and
primary insiders today have confirmed that they will exercise all of their
warrants, as follows:

• Investinor Direkte AS, a close associate of board member Ann-Tove Kongsnes:
4,875,920 warrants
• Helene Sundt AS, a close associate of board member Leiv Askvig: 2,050,577
warrants
• Sundt AS, a close associate of board member Leiv Askvig: 420,396 warrants
• Basen Kapital AS, a close associate of board member Leiv Askvig: 87,107
warrants
• Anders Wold, chair of the Company: 69,685 warrants
• Canica AS: 3,273,334 warrants

The exercise of the above-mentioned warrants, combined with the warrants
exercised by GEMH, accounts for 75% of the total warrants issued in conjunction
with the private placement completed in December 2024, corresponding to gross
proceeds of NOK 46 million.

The remaining warrants holders may exercise their warrants within 21 February
2026. Updates on the warrant exercise will follow in due course.

As soon as the Company has confirmation from the remaining warrants holders on
whether they will exercise their warrants, the Company will call for an
extraordinary general meeting to ensure that the relevant number of new shares
are issued.

Further, please find attached an updated corporate presentation which may also
be found in the Investors section of the Company’s webpage.

Please see the attached PDMR notification in accordance with Regulation EU
596/2014 (MAR) article 19 for further details.

About EXACT Therapeutics:
EXACT Therapeutics is a clinical-stage precision medicine company utilizing the
power of ultrasound to activate the proprietary drug PS101 and enhance the
clinical benefit of oncology therapies. PS101 has a unique mode of action and
may be combined with a wide range of therapeutic agents within oncology and
across a multitude of other indications, including brain diseases. EXACT
Therapeutics’ shares are traded on Euronext Growth Oslo (EXTX). Further
information may be found here:www.exact-tx.com

For further information, please contact:
Per Walday
CEO EXACT Therapeutics
Email: per.walday@exact-tx.com

More information:
Access the news on Oslo Bors NewsWeb site

664908_260205 EXACT Therapeutics - company presentation.pdf
664908_PDMR attachment - Warrants(22120906.1).pdf